3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Veristat and SFL, a Veristat company, will attend DIA Europe 2023
Veristat and SFL, a Veristat company will attend DIA Europe 2023 on 22 – 24 March in Basel, Switzerland. SFL, a Veristat company will host an exhibition booth (#13)
Our company leaders will engage with participants at the event and discuss their services including strategic and operational support from early development to regulatory approval, market access, quality assurance, pharmacovigilance, and supply chain management, as well as clinical development services including global clinical operations, biostatistics and programming.
Schedule A Meeting
If you would like to meet us at DIA Europe, feel free to contact us to arrange a meeting through the form. See you there!
Conference Details
Website: https://www.diaglobal.org/Flagship/DIA-Europe-2023
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...